Summary
- Kymera Therapeutics has filed proposed terms for its U.S. IPO.
- The firm is developing treatments for various skin and immune system conditions.
- KYMR is still at a preclinical stage, so the IPO is ultra-high-risk and likely more suited to institutional investors with long time horizons.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today ยป
Quick Take
Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is advancing treatment candidates for skin and immune system conditions.
KYMR is still some time away from beginning Phase 1 safety trials for its lead candidate, so the IPO may be more suited to long-term hold institutional investors.
Company & Technology
Watertown, Massachusetts-based Kymera was founded to create treatment options for hidradenitis suppurativa [HS] and atopic dermatitis [AD] as well as other immune system mediated conditions.
Management is headed by co-founder, president and CEO Nello Mainolfi, Ph.D., who was previously Head of Drug Discovery at Raze Therapeutics.
Below is a brief overview video of hidradenitis suppurativa:
